Pidilizumab (Anti-PDCD1 / PD-1 / CD279) | PD-1/PD-L1 antibody

Pidilizumab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody targeting human PD-1 (programmed cell death 1; PDCD1). It has immunomodulating and antitumor activities and can be used in treatment of metastatic melanoma. MW :144.48 KD.

Purity & Quality Control

≥99

Choose Selective PD-1/PD-L1 Inhibitors

Biological Activity

Description	Pidilizumab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody targeting human PD-1 (programmed cell death 1; PDCD1). It has immunomodulating and antitumor activities and can be used in treatment of metastatic melanoma. MW :144.48 KD.

References
[1] Albuquerque AO, et al. J Biomol Struct Dyn. 2022 Sep;40(14):6450-6462.

References

[1] Albuquerque AO, et al. J Biomol Struct Dyn. 2022 Sep;40(14):6450-6462.

Product Details

CAS No.	1036730-42-3
Isotype	Human IgG1
Source	CHO
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field